Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More

Buy Cipla: target of Rs 1100: Sharekhan

Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated April 16, 2021.

April 21, 2021 / 01:56 PM IST
  • bselive
  • nselive
Todays L/H

Sharekhan's research report on Cipla

Promising growth outlook for Indian pharmaceutical markets (IPM), which is expected to grow in high single digit to low double digit for FY2022 coupled with Covid led opportunities (albeit in the near term) could benefit Cipla’s India business. Ramp up in gAlbuterol in US followed by a strong product pipeline of respiratory assets as well as complex generics would fuel the growth in US sales. Healthy topline growth, strong earnings visibility, and a healthy balance sheet augur well and would be key positives going ahead.


We maintain Buy recommendation on Cipla Limited (Cipla) with a revised PT of Rs 1,100.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Apr 21, 2021 01:56 pm

stay updated

Get Daily News on your Browser